Abstracts tagged "biomarker"

Abstract Number: 0403 • ACR Convergence 2021
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Shervin Assassi¹, Christopher Denton², Maurizio Cutolo³, Tracy Luckhardt⁴, Claudia Diefenbach⁵, Carina Ittrich⁶, Margarida Alves⁷ and Masataka Kuwana⁸, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁴University of Alabama, Birmingham, AL, ⁵Boehringer Ingelheim Pharma GmBH, Biberach an der Riss, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁸Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Krebs von den Lungen-6 (KL-6), a marker of lung epithelial and endothelial injury, has been associated with progression of interstitial lung disease associated with…
Abstract Number: 0808 • ACR Convergence 2021
Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
Isaac Cheng¹, Ho So², Martin Li¹, Evelyn Chow¹, Chun Kwok Wong¹ and Lai-Shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²CUHK, Hong Kong, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: The use of treat-to-target (T2T) strategy in managing early rheumatoid arthritis (ERA) had been highly advocated in the past decades. Various international guideline utilized…
Abstract Number: 0863 • ACR Convergence 2021
Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan³, Sau Mei TSE² and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).Methods: Consecutive patients who fulfilled…
Abstract Number: 1373 • ACR Convergence 2021
Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Yossra Suliman³, Mohamed Alemam⁴, Rosha Mamita⁵, Jennifer Wang⁵, Ani Shahbazian⁶, Philip Clements⁷ and Christina Charles-Schoeman⁶, ¹University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ²Florida Universtity- College of Health and Human Sciences, Talahhasse, FL, ³Department of Clinical Pathology, Qena Faculty of Medicine, Assiut, Egypt, ⁴Department of Pathology< Qena Faculty of Medicine, South Valley University,, Assiut, Egypt, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA
Background/Purpose: Our understanding of the pathogenesis of systemic sclerosis (SSc) continues to evolve. Oxidative stress has been implicated in the pathophysiology of disease, but minimal…
Abstract Number: 0243 • ACR Convergence 2020
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
Pooja Kumari¹, Viswanathan Ramakrishnan², Jihad Obeid², Diane Kamen³ and Jim Oates⁴, ¹The university of Tennesse Health Science center, Memphis, TN, ²medical university of south carolina, south carolina, ³Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that leads to significant morbidity and mortality. Therefore, it is essential to…
Abstract Number: 920 • 2019 ACR/ARP Annual Meeting
Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome
Pui Lee¹, Grant Schulert ², Scott Canna ³, Yuelong Huang ⁴, Jacob Sundel ⁴, Mary Beth Son ¹, Lauren Henderson ¹, Peter Nigrovic ⁵, Jane Newburger ⁶, Fatma Dedeoglu ⁶, Mindy Lo ⁶, Esra Meidan ⁶, Ying Li ⁴, Olha Halyabar ⁶, Margaret Chang ⁷, Kacie Hoyt ⁶, Thuy Do ², Robert Sundel ⁸ and Rachel Blaustein ⁴, ¹Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁴Brigham and Women's Hospital, Boston, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA ; Department of Medicine, Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA., Boston, ⁶Boston Children's Hospital, Boston, ⁷Division of Immunology, Boston Children's Hospital, Boston, ⁸Boston Children’s Hospital, Harvard Medical School, Boston
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterized by a vicious cycle of immune cell activation and…
Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Kathleen Sullivan¹, Jonathan Burnham ², Kathleen O'Neil ³, Laura Schanberg ⁴, Emily von Scheven ⁵, Marisa Klein-Gitelman ⁶ and Patricia Costa Reis ⁷, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Indiana University, Indianapolis, IN, ⁴Duke University Medical Center, Durham, NC, ⁵UCSF, San Francisco, CA, ⁶Lurie Children's Hospital, Chicago, IL, ⁷Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…
Abstract Number: 580 • 2017 ACR/ARHP Annual Meeting
Tenascin-C, a TLR 4 Endogenous Ligand Levels Are Increased in Ankylosing Spondylitis
Latika Gupta, Shruti Bhattacharya and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Monocytes of patients with Ankylosing Spondylitis (AS) over-express Toll-like receptor (TLR) 4 on their monocytes. Tenascin-C (TNC) is an extracellular-matrix-glycoprotein and acts as an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].